

Delta positive nasopharyngeal swabs		
Sex	Female	25
	Male	28
Age (Median; range)		61 (24;98)
Immunodeficiency		6
Vaccination statut (Number of patients)		
	Unvaccinated	33
	1st dose	2
	2nd dose	10
	3rd dose	7
	4th dose	0
Sampling days post-symptom (median; range)		7 (0;30)

BA.1 positive nasopharyngeal swabs		
Sex	Female	49
	Male	32
Age (Median; range)		41 (19;98)
Immunodeficiency		7
Vaccination statut (Number of patients)		
	Unvaccinated	12
	1st dose	6
	2nd dose	41
	3rd dose	13
	4th dose	1
Sampling days post-symptom (median; range)		2 (0;21)

1 month post-third dose		
Sex	Female	8
	Male	10
Age (Median; range)		60 (36;95)
Immunodeficiency		0
Previous COVID-19		0
1st dose		Jan 6 - April 19, 2021
2nd dose		Jan 26 - May 31, 2021
3rd dose		Aug 31 - Dec 10, 2021
Sampling days post-vaccination (median; range)		34 days (24;54)

  

4 months post-third dose		
Sex	Female	3
	Male	7
Age (Median; range)		63 (53;94)
Immunodeficiency		0
Previous COVID-19		0
1st dose		Jan 8 - Feb 4, 2021
2nd dose		Jan 29 - March 3, 2021
3rd dose		Sept 6 - Nov 16, 2021
Sampling days post-vaccination (median; range)		132 days (99;232)

  

3 months post-breakthrough BA.1/2		
Sex	Female	7
	Male	9
Age (Median; range)		58 (34;72)
Immunodeficiency		0
Vaccination statut (Number of patients)		
3 doses		16
Breakthrough BA.1		Dec 26, 2021 - Jun 22, 2022
Sampling days post-breakthrough (median; range)		84 days (44;109)

  

8 months post-breakthrough BA.1/2		
Sex	Female	5
	Male	8
Age (Median; range)		59 (36;72)
Immunodeficiency		0
Vaccination statut (Number of patients)		
3 doses		13
Breakthrough BA.1/BA.2		Dec 26, 2021 - April 14, 2022
Sampling days post-breakthrough (median; range)		234 days (142;289)

  

2 months post-breakthrough BA.5		
Sex	Female	10
	Male	5
Age (Median; range)		62 (22;93)
Immunodeficiency		0
Vaccination statut (Number of patients)		
2 doses		1
3 doses		10
4 doses		4
Breakthrough BA.5 (days of positive PCR)		July 7 - Oct 10, 2022
Sampling days post-breakthrough (median; range)		50 days (12;127)